8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Mar 12, 2026·SEC
OnKure Therapeutics, Inc.(OKUR)Earnings, Financials & Key Ratios
OKUR•NASDAQ
Price updated Jun 11, 2026
AboutOnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.Show more
- Revenue$0
- EBITDA-$62M-15.6%
- Net Income-$60M-13.0%
- EPS (Diluted)-4.40-11.4%
- ROE-74.39%+98.6%
- Debt/Equity0.01-6.5%
OKUR Key Insights
OnKure Therapeutics, Inc. (OKUR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 85 (top 15%)
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Profits declining 25.0% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when OKUR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OKUR Price & Volume
OnKure Therapeutics, Inc. (OKUR) stock price & volume — 10-year historical chart
Loading chart...
OKUR Growth Metrics
OnKure Therapeutics, Inc. (OKUR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM36.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM16.25%
Return on Capital
10 Years-77.75%
5 Years-85.58%
3 Years-116.72%
Last Year-78.41%
OKUR Recent Earnings
OnKure Therapeutics, Inc. (OKUR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
May 5, 2026EPS
$1.11
Est $0.74
-49.5%
Revenue
—
Est $166,667
Q2 2026
Mar 12, 2026EPS
$0.99
Est $1.15
+13.9%
Revenue
—
Est $16M
Q4 2025
Nov 6, 2025EPS
$1.09
Est $1.20
+9.2%
Revenue
—
Q3 2025
Aug 12, 2025EPS
$1.14
Est $1.23
+7.3%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $1.11vs $0.74-49.5% | —vs $166,667 |
| Q2 2026 | Mar 12, 2026 | $0.99vs $1.15+13.9% | —vs $16M |
| Q4 2025 | Nov 6, 2025 | $1.09vs $1.20+9.2% | — |
| Q3 2025 | Aug 12, 2025 | $1.14vs $1.23+7.3% | — |
Based on last 12 quarters of dataView full earnings history →
OKUR Peer Comparison
OnKure Therapeutics, Inc. (OKUR) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 6.77B | 82.96 | -22.48 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ARVN | 457.46M | 7.09 | -5.54 | -0.3% | -247.54% | -44.39% | 0.02 | |
 PRAX | 7.16B | 247.98 | -18.40 | -100% | -43.02% | 0.00 | ||
 TNGX | 3.46B | 29.82 | -34.28 | 48.29% | -188.15% | -41.54% | 0.10 | |
 AUPH | 2.04B | 15.85 | 7.66 | 20.38% | 99.97% | 64.48% | 0.13 | |
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 | |||
 RCUS | 2.35B | 23.30 | -7.08 | -4.26% | -156.36% | -68.97% | 0.16 | |
 ERAS | 4.36B | 14.01 | -31.84 | -77.01% | 0.14 |
Compare OKUR vs Peers
OnKure Therapeutics, Inc. (OKUR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OKUR Income Statement
OnKure Therapeutics, Inc. (OKUR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - |
Cost of Goods Sold | 37K | 50K | 0 | 0 | 0 | 830K | 0 |
COGS % of Revenue | - | - | - | - | - | - | - |
Gross Profit | -37K▲ 0% | -50K▼ 35.1% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | -830K▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - |
Gross Profit Growth % | - | -35.14% | 100% | - | - | - | - |
Operating Expenses | 19.52M | 39.77M | 29.77M | 36.93M | 54.39M | 62.12M | 61.56M |
OpEx % of Revenue | - | - | - | - | - | - | - |
Selling, General & Admin | 3.61M | 11.65M | 3.9M | 4.82M | 10.59M | 14.69M | 14.61M |
SG&A % of Revenue | - | - | - | - | - | - | - |
Research & Development | 15.91M | 28.12M | 25.86M | 32.12M | 43.8M | 48.26M | 46.95M |
R&D % of Revenue | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -830K | 0 |
Operating Income | -19.55M▲ 0% | -39.82M▼ 103.7% | -29.77M▲ 25.2% | -36.93M▼ 24.1% | -54.39M▼ 47.3% | -62.95M▼ 15.7% | -61.56M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - |
Operating Income Growth % | - | -103.65% | 25.24% | -24.08% | -47.25% | -15.75% | - |
EBITDA | -19.52M | -39.77M | -29.38M | -36.37M | -53.72M | -62.12M | -60.95M |
EBITDA Margin % | - | - | - | - | - | - | - |
EBITDA Growth % | - | -103.78% | 26.12% | -23.81% | -47.7% | -15.63% | 11.43% |
D&A (Non-Cash Add-back) | 37K | 50K | 387K | 560K | 662K | 830K | 618K |
EBIT | -19.46M | -39.77M | -29.77M | -35.31M | -52.37M | -62.95M | -43.58M |
Net Interest Income | 0 | 0 | 254K | 1.62M | 1.71M | 3.44M | 2.36M |
Interest Income | 0 | 0 | 254K | 1.62M | 2.01M | 3.44M | 2.82M |
Interest Expense | 0 | 0 | 0 | 0 | 300K | 0 | 8K |
Other Income/Expense | 87K | 48K | 254K | 1.62M | 1.71M | 3.43M | 2.36M |
Pretax Income | -19.46M▲ 0% | -39.77M▼ 104.3% | -29.51M▲ 25.8% | -35.31M▼ 19.6% | -52.67M▼ 49.2% | -59.52M▼ 13.0% | -43.59M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -19.46M▲ 0% | -39.77M▼ 104.3% | -29.51M▲ 25.8% | -35.31M▼ 19.6% | -52.67M▼ 49.2% | -59.52M▼ 13.0% | -43.59M▲ 0% |
Net Margin % | - | - | - | - | - | - | - |
Net Income Growth % | - | -104.32% | 25.79% | -19.65% | -49.17% | -12.99% | 36.78% |
Net Income (Continuing) | -19.46M | -39.77M | -29.51M | -35.31M | -52.67M | -59.52M | -43.59M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -7.74▲ 0% | -21.92▼ 183.2% | -2.21▲ 89.9% | -2.65▼ 19.9% | -3.95▼ 49.1% | -4.40▼ 11.4% | -3.19▲ 0% |
EPS Growth % | - | -183.2% | 89.92% | -19.91% | -49.06% | -11.39% | 16.25% |
EPS (Basic) | -7.74 | -21.92 | -2.21 | -2.65 | -3.95 | -4.40 | - |
Diluted Shares Outstanding | 2.51M | 1.81M | 13.34M | 13.34M | 13.34M | 13.52M | 13.67M |
Basic Shares Outstanding | 2.51M | 1.81M | 13.34M | 13.34M | 13.34M | 13.52M | 13.67M |
Dividend Payout Ratio | - | - | - | - | - | - | - |
OKUR Balance Sheet
OnKure Therapeutics, Inc. (OKUR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Total Current Assets | 55.02M | 153.73M | 13.62M | 33.77M | 113M | 60.84M | 197.48M |
Cash & Short-Term Investments | 53.61M | 147.67M | 11.54M | 29.88M | 110.76M | 59.05M | 192.11M |
Cash Only | 53.61M | 124.66M | 11.54M | 29.88M | 110.76M | 59.05M | 192.11M |
Short-Term Investments | 0 | 23.01M | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - |
Other Current Assets | 1.41M | 6.06M | 840K | 0 | 0 | 1.79M | 5.38M |
Total Non-Current Assets | 196K | 290K | 2.38M | 1.97M | 1.9M | 1.28M | 1.21M |
Property, Plant & Equipment | 69K | 212K | 2.05M | 1.91M | 1.79M | 1M | 807K |
Fixed Asset Turnover | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 127K | 78K | 329K | 58K | 109K | 273K | 405K |
Total Assets | 55.22M▲ 0% | 154.02M▲ 178.9% | 16M▼ 89.6% | 35.73M▲ 123.4% | 114.91M▲ 221.6% | 62.12M▼ 45.9% | 198.69M▲ 0% |
Asset Turnover | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 178.92% | -89.61% | 123.35% | 221.56% | -45.94% | 284.68% |
Total Current Liabilities | 4.58M | 6.2M | 5.54M | 7.29M | 10.53M | 5.92M | 14.33M |
Accounts Payable | 0 | 0 | 2.52M | 3.42M | 2.97M | 1.43M | 11.02M |
Days Payables Outstanding | - | - | - | - | - | 630.17 | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 549K | 409K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4.58M | 6.2M | 1.46M | 1.66M | 3.17M | 3.94M | 2.9M |
Current Ratio | 12.01x | 24.79x | 2.46x | 4.64x | 10.73x | 10.28x | 13.78x |
Quick Ratio | 12.01x | 24.79x | 2.46x | 4.64x | 10.73x | 10.28x | 13.78x |
Cash Conversion Cycle | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 92.76M | 611K | 64.88M | 130.29M | 549K | 12K | 12K |
Long-Term Debt | 92.72M | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 486K | 466K | 549K | 0 | 267K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 444K | 64.39M | 129.82M | 0 | 12K | 12K |
Total Liabilities | 97.34M | 6.81M | 70.42M | 137.58M | 11.08M | 5.93M | 14.34M |
Total Debt | 92.72M | 0 | 637K | 674K | 1.08M | 549K | 409K |
Net Debt | 39.11M | -124.66M | -10.91M | -29.2M | -109.68M | -58.5M | -191.7M |
Debt / Equity | - | - | - | - | 0.01x | 0.01x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | 3.15x |
Interest Coverage | - | - | - | - | -174.58x | - | -5448.00x |
Total Equity | -42.12M▲ 0% | 147.21M▲ 449.5% | -54.42M▼ 137.0% | -101.84M▼ 87.1% | 103.83M▲ 202.0% | 56.18M▼ 45.9% | 184.35M▲ 0% |
Equity Growth % | - | 449.55% | -136.97% | -87.15% | 201.95% | -45.89% | 210.48% |
Book Value per Share | -16.75 | 81.14 | -4.08 | -7.63 | 7.78 | 4.16 | 13.48 |
Total Shareholders' Equity | -42.12M | 147.21M | -54.42M | -101.84M | 103.83M | 56.18M | 184.35M |
Common Stock | 1K | 3K | 1K | 0 | 1K | 1K | 4K |
Retained Earnings | -44.96M | -84.73M | -57.07M | -102.05M | -154.72M | -214.24M | -229.4M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 34K | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OKUR Cash Flow Statement
OnKure Therapeutics, Inc. (OKUR) cash flow — operating, investing & free cash flow history
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Cash from Operations | -18.54M | -37.98M | -26.95M | -34.55M | -51.12M | -51.83M | -50.76M |
Operating CF Margin % | - | - | - | - | - | - | - |
Operating CF Growth % | - | -104.91% | 29.04% | -28.17% | -47.97% | -1.39% | -74.52% |
Net Income | -19.46M | -39.77M | -29.51M | -35.31M | -52.67M | -59.52M | -43.59M |
Depreciation & Amortization | 37K | 50K | 387K | 560K | 662K | 830K | 821K |
Stock-Based Compensation | 0 | 0 | 48K | 199K | 4.53M | 11.63M | 11.67M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 378K | 4.54M | 0 | 0 | 316K | 6K | -758K |
Working Capital Changes | 514K | -2.8M | 2.12M | 6K | -3.95M | -4.78M | -3.74M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 1.71M | -5.93M | -4.54M | -2.41M |
Cash from Investing | 7.38M | -23.38M | -1.13M | -246K | 15.87M | -46K | -33K |
Capital Expenditures | -24K | -198K | -1.13M | -246K | -52K | -46K | -33K |
CapEx % of Revenue | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -44.1M | 0 | 0 | 0 | 0 |
Cash from Financing | 47.27M | 132.41M | 26.46M | 53.13M | 116.13M | 163K | 146.24M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 6M | 0 | 0 |
Equity Issued (Net) | 47.27M | 132.41M | 27.84M | 53.85M | 58.91M | 203K | 240K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | -1.38M | -723K | 51.22M | -40K | 146M |
Net Change in Cash | 36.11M▲ 0% | 71.05M▲ 96.7% | -1.62M▼ 102.3% | 18.33M▲ 1230.3% | 80.89M▲ 341.2% | -51.71M▼ 163.9% | 95.44M▲ 0% |
Free Cash Flow | -18.56M▲ 0% | -38.18M▼ 105.7% | -28.09M▲ 26.4% | -34.79M▼ 23.9% | -51.17M▼ 47.1% | -51.87M▼ 1.4% | -50.79M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - |
FCF Growth % | - | -105.72% | 26.44% | -23.87% | -47.07% | -1.38% | 2.79% |
FCF per Share | -7.38 | -21.04 | -2.11 | -2.61 | -3.84 | -3.84 | -3.71 |
FCF Conversion (FCF/Net Income) | 0.95x | 0.96x | 0.91x | 0.98x | 0.97x | 0.87x | 1.17x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OKUR Key Ratios
OnKure Therapeutics, Inc. (OKUR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -75.68% | -63.61% | - | -5304.43% | -74.39% | -45.27% |
| Return on Invested Capital (ROIC) | -305.62% | - | - | - | - | 1069.95% |
| Debt / Equity | - | - | - | 0.01x | 0.01x | 0.00x |
| Interest Coverage | - | - | - | -174.58x | - | -5448.00x |
| FCF Conversion | 0.96x | 0.91x | 0.98x | 0.97x | 0.87x | 1.17x |
Related:OKUR Dividend History·OKUR Revenue History·OKUR Price History·OKUR P/E History·OKUR Financial Ratios·OKUR Institutional Holders
OKUR SEC Filings & Documents
OnKure Therapeutics, Inc. (OKUR) SEC filings — annual & quarterly reports (10-K, 10-Q)
OKUR Frequently Asked Questions
OnKure Therapeutics, Inc. (OKUR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
OnKure Therapeutics, Inc. (OKUR) grew revenue by 0.0% over the past year. Growth has been modest.
OnKure Therapeutics, Inc. (OKUR) reported a net loss of $43.6M for fiscal year 2025.
Dividend & Returns
OnKure Therapeutics, Inc. (OKUR) has a return on equity (ROE) of -74.4%. Negative ROE indicates the company is unprofitable.
OnKure Therapeutics, Inc. (OKUR) had negative free cash flow of $50.8M in fiscal year 2025, likely due to heavy capital investments.